HealthDay News — Nivolumab in combination with contact immunotherapy can successfully treat in-transit melanoma, according to two case reports published online December 12 in the Journal of Dermatology.
Publications
Scientists at The Wistar Institute are using revolutionary mouse ‘avatar’ models to discover effective combination treatments that may prolong responses and survival rates.
Melanoma patients who receive treatment with targeted therapies experience an initial response that feels like a cure, but that early excitement is quickly dampened when patients relapse as their cancers find alternative pathways in our cells to grow and spread. With melanoma so good at escaping targeted treatments, there’s a dire need to halt these cancers in their tracks to prolong good responses and promote longer, healthier lives.
Blocking melanoma’s escape: Avatars break theraping resistance in relapsed cancers
Melanoma patients who receive treatment with targeted therapies experience an initial response that feels like a cure, but that early excitement is quickly dampened when patients relapse as their cancers find alternative pathways in our cells to grow and spread. With melanoma so good at escaping targeted treatments, there’s a dire need to halt these cancers in their tracks to prolong good responses and promote longer, healthier lives.
FDA Expands Pembrolizumab Label for Melanoma
The US Food and Drug Administration (FDA) recently expanded its approval of pembrolizumab (Keytruda) to include the initial treatment of patients with unresectable or metastatic melanoma. In 2014, pembrolizumab was approved for patients with unresectable or metastatic melanoma who progressed after treatment with ipilimumab and, if BRAF V600–mutation positive, a BRAF inhibitor.